These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28531230)

  • 41. US Department of Defense contributions to malaria surveillance.
    Saunders D; Duplessis C; Lescano A; Andagalu B; Thomas A; Fukuda M; Cummings J;
    Lancet Infect Dis; 2013 Apr; 13(4):293-4. PubMed ID: 23538221
    [No Abstract]   [Full Text] [Related]  

  • 42. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot.
    Taylor SM; Juliano JJ
    J Infect Dis; 2014 Aug; 210(3):335-7. PubMed ID: 24610873
    [No Abstract]   [Full Text] [Related]  

  • 43. Artemisinin-resistant malaria in Asia.
    Noedl H; Socheat D; Satimai W
    N Engl J Med; 2009 Jul; 361(5):540-1. PubMed ID: 19641219
    [No Abstract]   [Full Text] [Related]  

  • 44. Parasite clearance after malaria therapy: staying a step ahead of drug resistance.
    Karunajeewa HA
    BMC Med; 2015 Oct; 13():251. PubMed ID: 26429335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of antimalarial self-medication in illegal gold miners in French Guiana: a pathway towards artemisinin resistance.
    Douine M; Lazrek Y; Blanchet D; Pelleau S; Chanlin R; Corlin F; Hureau L; Volney B; Hiwat H; Vreden S; Djossou F; Demar M; Nacher M; Musset L
    J Antimicrob Chemother; 2018 Jan; 73(1):231-239. PubMed ID: 29045645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of artemisinin resistance in Plasmodium falciparum malaria.
    Suresh N; Haldar K
    Curr Opin Pharmacol; 2018 Oct; 42():46-54. PubMed ID: 30077118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.
    Gordi T; Xie R; Jusko WJ
    Br J Clin Pharmacol; 2005 Dec; 60(6):594-604. PubMed ID: 16305583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.
    Fernández-Martínez A; Mula P; Cravo P; Charle P; Amor A; Ncogo P; Benito A; Berzosa P
    Am J Trop Med Hyg; 2013 Jan; 88(1):43-47. PubMed ID: 23185077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy.
    Moore BR; Laman M; Salman S; Batty KT; Page-Sharp M; Hombhanje F; Manning L; Davis TM
    Drugs; 2016 May; 76(7):789-804. PubMed ID: 27075024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations.
    Tindana P; de Haan F; Amaratunga C; Dhorda M; van der Pluijm RW; Dondorp AM; Cheah PY
    Malar J; 2021 Feb; 20(1):119. PubMed ID: 33639946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Artemisinin: discovery from the Chinese herbal garden.
    Miller LH; Su X
    Cell; 2011 Sep; 146(6):855-8. PubMed ID: 21907397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Observing in real time the evolution of artemisinin resistance in Plasmodium falciparum.
    Sibley CH
    BMC Med; 2015 Mar; 13():67. PubMed ID: 25889405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Will the in situ activator(s) of artemisinin please stand up?
    Auparakkitanon S; Wilairat P; Wilairat P
    Mol Biochem Parasitol; 2022 Mar; 248():111461. PubMed ID: 35122935
    [No Abstract]   [Full Text] [Related]  

  • 54. Were medicine quality and pharmaceutical management contributing factors in diminishing artemisinin efficacy in Guyana and Suriname?
    Pribluda VS; Evans L; Barillas E; Marmion J; Lukulay P; Chang J
    Malar J; 2014 Mar; 13():77. PubMed ID: 24581434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implications of the MDA Trial in Southern Province, Zambia, for Malaria Control and Elimination.
    Steketee RW; Miller JM; Chizema Kawesha E
    Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):98-101. PubMed ID: 32618248
    [No Abstract]   [Full Text] [Related]  

  • 56. Artemisinin based combination therapy in travel medicine.
    Jelinek T
    Travel Med Infect Dis; 2013; 11(1):23-8. PubMed ID: 23465532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The first case of artemisinin treatment failure of Plasmodium falciparum imported to Oman from Tanzania.
    Subudhi AK; Bienvenu AL; Bonnot G; Abu-Shamma R; Khamis F; Lawati HAAA; Picot S; Petersen E; Pain A
    J Travel Med; 2023 May; 30(3):. PubMed ID: 35960997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Artemisinin-Resistant Plasmodium falciparum in Africa.
    Lu F; Culleton R; Cao J
    N Engl J Med; 2017 Jul; 377(3):306. PubMed ID: 28723328
    [No Abstract]   [Full Text] [Related]  

  • 59. Artesunate-quercetin/luteolin dual drug nanofacilitated synergistic treatment for malaria: A plausible approach to overcome artemisinin combination therapy resistance.
    Puttappa N; Kumar RS; Yamjala K
    Med Hypotheses; 2017 Nov; 109():176-180. PubMed ID: 29150282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Artemisinin-resistant malaria in the Asia-Pacific region.
    Tulloch J; David B; Newman RD; Meek S
    Lancet; 2013 Jun; 381(9881):e16-7. PubMed ID: 23122219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.